Copyright © 1999-2005 Inspire Pharmaceuticals Inc. All rights reserved


TIGER-2 Information

Inspire Reports First Quarter 2008 Financial Results - Q1 2008 Revenue Increased by 35% over Q1 2007
Webcast
    Replay Conference Call
    800-642-1687 (US)
    706-645-9291(International)
    ID number is 44700402
    (available until May 22, 2008)

Inspire Announces Poster Presentations at 2008 Association for Research in Vision and Ophthalmology Annual Meeting

Inspire Announces Webcasts of Presentations at Morgan Stanley and Deutsche Bank Healthcare Conferences
Morgan Stanley Webcast
      May 1, 2008 11:20am ET
Deutsche Bank Webcast
      May 6, 2008 11:30am ET

Inspire to Discontinue Development of Epinastine Nasal Spray

Inspire Announces Poster Presentation at American Society of Cataract and Refractive Surgery Annual Symposium

Inspire Announces Poster Presentations at 2008 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting

Inspire Announces Webcast of Presentation at Cowen and Company Health Care Conference

Inspire Director William R. Ringo to Resign Board Position

Inspire Announces Webcast of Presentation at Susquehanna Healthcare Conference

Inspire Reports Fourth Quarter and Full Year 2007 Financial Results

Inspire Initiates Second Phase 3 Cystic Fibrosis Trial

Inspire Announces Webcasts of Presentations at BIO CEO and Roth Growth Stock Conferences

Inspire Provides 2008 Financial Guidance

Inspire Announces Its Termination of Bilastine Licensing Agreement

Inspire Initiates Phase 3 Trial of Epinastine Nasal Spray for Allergic Rhinitis

 

 

 

 

 

 

 

Page last updated: 08-May-2008